Development and Validation of a Deep Learning CT Signature to Predict Survival and Chemotherapy Benefit in Gastric Cancer: A Multicenter, Retrospective Study. Issue 6 (December 2021)

• Record Type: Journal Article
• Authors: Jiang, Yuming; Jin, Cheng; Yu, Heng; Wu, Jia; Chen, Chuanli; Yuan, Qingyu; Huang, Weicai; Hu, Yanfeng; Xu, Yikai; Zhou, Zhiwei; Fisher, George A.; Li, Guoxin; Li, Ruijiang
• Is Part Of: Annals of surgery. Volume 274:Issue 6(2021)
• Publication Date: 2021-12
• Subjects: chemotherapy benefits -- deep learning -- gastric cancer -- prognosis; Surgery -- Periodicals; 617.005
• DOI: 10.1097/SLA.0000000000003778
• Languages: English
• ISSNs: 0003-4932

Abstract

Abstract : Objective: We aimed to develop a deep learning-based signature to predict prognosis and benefit from adjuvant chemotherapy using preoperative computed tomography (CT) images. Background: Current staging methods do not accurately predict the risk of disease relapse for patients with gastric cancer. Methods: We proposed a novel deep neural network (S-net) to construct a CT signature for predicting disease-free survival (DFS) and overall survival in a training cohort of 457 patients, and independently tested it in an external validation cohort of 1158 patients. An integrated nomogram was constructed to demonstrate the added value of the imaging signature to established clinicopathologic factors for individualized survival prediction. Prediction performance was assessed with respect to discrimination, calibration, and clinical usefulness. Results: The DeLIS was associated with DFS and overall survival in the overall validation cohort and among subgroups defined by clinicopathologic variables, and remained an independent prognostic factor in multivariable analysis ( P < 0.001). Integrating the imaging signature and clinicopathologic factors improved prediction performance, with C-indices: 0.792–0.802 versus 0.719–0.724, and net reclassification improvement 10.1%–28.3%. Adjuvant chemotherapy was associated with improved DFS in stage II patients with high-DeLIS [hazard ratio = 0.362 (95% confidence interval 0.149–0.882)] and stage III patients with high- and intermediate-DeLIS [hazard ratio = 0.611 (0.442–0.843); 0.633 (0.433–0.925)]. On the other hand, adjuvant chemotherapy did not affect survival for patients with low-DeLIS, suggesting a predictive effect ( P interaction = 0.048, 0.016 for DFS in stage II and III disease). Conclusions: The proposed imaging signature improved prognostic prediction and could help identify patients most likely to benefit from adjuvant chemotherapy in gastric cancer. Abstract : Supplemental Digital Content is available in the text